Pyxis Oncology names Thomas Civik permanent CEO and board chair

Pyxis Oncology, Inc. (Nasdaq: PYXS) has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026, according to a company statement. Civik had served as Interim Chief Executive Officer since February 2026 and as a board member since 2021.

John Flavin, co-founder and founding Chairman of Pyxis Oncology, will transition to Lead Independent Director and continue serving on the board.

"Over the past several months, Tom has demonstrated the leadership, strategic focus and disciplined execution the Board believes are needed as Pyxis Oncology approaches key clinical milestones for MICVO," Flavin said.

Civik previously served as Chairman of ImCheck Therapeutics, which was acquired by Ipsen, and Repare Therapeutics, which was acquired by Xoma. He also served as President and CEO of Five Prime Therapeutics until its acquisition by Amgen for $1.9 billion in April 2021. Earlier roles included Chief Commercial Officer at Foundation Medicine and a 17-year career at Genentech.

Pyxis Oncology expects to report updated data from an ongoing MICVO Phase 1 monotherapy study in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma in fall 2026. The company also expects to report updated data from its Phase 1/2 combination study with pembrolizumab in first-line recurrent/metastatic head and neck squamous cell carcinoma in the fourth quarter of 2026.

You May Also Be Interested In

• After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
• Grosvenor closes $5.25M subscription receipt private placement
• Vistra prices $1.5B junior subordinated notes offering due 2057